Therapeutic response to rituximab in seropositive neuromyelitis optica: Experience from a tertiary care center in South India.
Joe JamesV Abdul GafoorJames JoseB SmitaNeetha BalaramPublished in: Journal of neurosciences in rural practice (2023)
Rituximab exhibited high efficacy and good safety in seropositive NMO. Larger trials in this subgroup are warranted to confirm these findings.